SCHEMBL16748522

SCHEMBL16748522

CCc1nc2cc(F)c(F)cc2n1-c1nc(N)nc(Nc2ccc(C(F)(F)F)cc2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BMI1 P35226 9/20 0.52
PIK3CD O00329 1/20 0.42
PIK3CA P42336 1/20 0.42
PIK3CB P42338 1/20 0.42
MTOR P42345 1/20 0.42
PIK3CG P48736 1/20 0.42
AGPAT2 O15120 1/20 0.37
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
CYBB P04839 1/20 0.35
NOX5 Q96PH1 1/20 0.35
NOX3 Q9HBY0 1/20 0.35
NOX4 Q9NPH5 1/20 0.35
NOX1 Q9Y5S8 1/20 0.35
DHFR P00374 1/20 0.35
KCNH3 Q9ULD8 1/20 0.34
GALR2 O43603 1/20 0.34
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16748477 0.90 BMI1 (0.50) BMI1PIK3CDPIK3CAPIK3CBMTOR
SCHEMBL16740754 0.89 BMI1 (0.55) BMI1AGPAT2LMNAMAPTCTSS
SCHEMBL16740827 0.89 BMI1 (0.65) BMI1AGPAT2LMNAMAPTDHFR
SCHEMBL16740765 0.86 BMI1 (0.63) BMI1PIK3CDPIK3CAPIK3CBMTOR
SCHEMBL16740864 0.85 BMI1 (0.48) BMI1AGPAT2LMNAMAPTCTSS
SCHEMBL16540547 0.84 BMI1 (0.61) BMI1KCNH3GALR2JAK2
SCHEMBL16748519 0.84 BMI1 (0.40) BMI1PIK3CDPIK3CAPIK3CBMTOR
SCHEMBL16748512 0.84 BMI1 (0.54) BMI1PIK3CDPIK3CAPIK3CBMTOR
SCHEMBL16740821 0.83 BMI1 (0.46) BMI1LMNAMAPTCTSSCTSK
SCHEMBL16748495 0.83 BMI1 (0.50) BMI1AGPAT2LMNAMAPTCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B BMI1 1/4885PIK3CD 2974/4885PIK3CA 3534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.